Statistics from Altmetric.com
New progressive tobacco control legislation in Israel restricted advertising of all tobacco and related products, including heated tobacco products and electronic cigarettes. The three main elements comprised: (1) advertising bans in all media, including broadcast, outdoor, internet and print media, but excluding newspapers (effective March 2019); (2) bans on point-of-sale displays except in specialised tobacco and alcohol outlets (effective January 2020); and (3) plain packaging (effective January 2020).1–3 During the initial implementation phase, an active tobacco control coalition communicated via social media (‘WhatsApp’) regarding tobacco industry tactics to bypass legislative efforts, test the limits of the legislation and/or test the government’s ability to enforce the legislation. The coalition included civil society and professional organisations from a wide range of disciplines, including public health, medicine, public policy, public administration and communications.3 Table 1 provides a detailed account of the policies, industry reactions and lessons learnt (also see figures 1 and 2).
Contributors HL, CJB, LA and YB-Z conceived the idea for the manuscript. YB-Z, SK, HHG, EG and HL collected the data. YB-Z wrote the manuscript with all other authors contributing. All authors reviewed and authorised the final version submitted.
Funding This research was supported by the National Cancer Institute (R01CA239178-01A1; MPIs: CJB, HL). Dr Berg is also supported by the National Cancer Institute (R01CA215155-01A1; PI: CJB; R01CA179422-01; PI: CJB), the US Fogarty International Center/National Cancer Institute (1R01TW010664-01; MPIs: CJB, Kegler), and Fogarty/NIEHS (D43ES030927-01; MPIs: CJB, Marsit, Sturua).
Competing interests YB-Z has received fees for lectures from Pfizer Israel Ltd, Novartis NCH and GSK Consumer Health (distributors of smoking cessation pharmacotherapy in Israel) in the past (2012-07/2019). HL had received fees for lectures from Pfizer Israel Ltd (distributor of a smoking cessation pharmacotherapy in Israel) in 2017. LA receives royalties for the sale of Text2Quit and is a shareholder in Welltok, Inc.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the article
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.